» Articles » PMID: 37766910

The SFlt-1/PlGF Ratio Trend Is Useful in Predicting Preeclampsia Severity in Hyperreactio Luteinalis Complicated with Preeclampsia

Overview
Publisher Wiley
Date 2023 Sep 28
PMID 37766910
Authors
Affiliations
Soon will be listed here.
Abstract

Hyperreactio luteinalis (HL) is a rare condition that presents as bilateral ovarian enlargement during pregnancy. Typically, it is thought to be caused by increased production of human chorionic gonadotropin (hCG) associated with gestational trophoblastic diseases or multiple pregnancies. The prognosis is relatively good, with many cases resulting in term birth. However, some obstetric complications, such as preeclampsia (PE) and preterm births, have been reported. We present a serious case of HL with subsequent PE that resulted in preterm delivery at 31 weeks of gestation. The soluble fms-like tyrosine kinase-1 (sFlt-1)/placental growth factor (PlGF) ratio was very high at the onset of PE at 24 weeks of gestation, followed by a modest decline, which then increased in proportion to the exacerbation of symptoms. Since HL cases have also been reported to be associated with PE, repeated measurement of the sFlt-1/PlGF ratio proved useful for better pregnancy management.

References
1.
Grgic O, Radakovic B, Barisic D . Hyperreactio luteinalis could be a risk factor for development of HELLP syndrome: case report. Fertil Steril. 2008; 90(5):2008.e13-6. DOI: 10.1016/j.fertnstert.2008.06.053. View

2.
Haq A . Hyperreactio luteinalis associated with pregnancy induced hypertension. J Coll Physicians Surg Pak. 2010; 20(2):137-9. DOI: 02.2010/JCPSP.137139. View

3.
Gatongi D, Madhvi G, Tydeman G, Hasan A . A case of hyperreactio luteinalis presenting with eclampsia. J Obstet Gynaecol. 2006; 26(5):465-7. DOI: 10.1080/01443610600759244. View

4.
Cavoretto P, Giorgione V, Sigismondi C, Mangili G, Serafini A, Dallagiovanna C . Hyperreactio luteinalis: timely diagnosis minimizes the risk of oophorectomy and alerts clinicians to the associated risk of placental insufficiency. Eur J Obstet Gynecol Reprod Biol. 2014; 176:10-6. DOI: 10.1016/j.ejogrb.2014.02.017. View

5.
Lai J, Larroca S, Peeva G, Poon L, Wright D, Nicolaides K . Competing risks model in screening for preeclampsia by serum placental growth factor and soluble fms-like tyrosine kinase-1 at 30-33 weeks' gestation. Fetal Diagn Ther. 2014; 35(4):240-8. DOI: 10.1159/000359968. View